# A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Source: https://onco.cc/trials/nct07198633/  
OnCo record `nct07198633` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of QLC5508, Abiraterone acetate, Enzalutamide in prostate cancer, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer is a phase 1/2 interventional study registered as NCT07198633 by Qilu Pharmaceutical Co., Ltd., with 212 participants planned, started 2025-11-05 and due to reach its primary completion in 2026-12. Interventions recorded: QLC5508, abiraterone acetate, enzalutamide, QLH12016. Conditions listed: Advanced Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07198633
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 212

## Sources

- ClinicalTrials.gov NCT07198633: https://clinicaltrials.gov/study/NCT07198633

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [QLC5508](https://onco.cc/drugs/qlc5508/), [QLH12016](https://onco.cc/drugs/qlh12016/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07198633.json